[go: up one dir, main page]

BG101833A - Гуаниново производно - Google Patents

Гуаниново производно

Info

Publication number
BG101833A
BG101833A BG101833A BG10183397A BG101833A BG 101833 A BG101833 A BG 101833A BG 101833 A BG101833 A BG 101833A BG 10183397 A BG10183397 A BG 10183397A BG 101833 A BG101833 A BG 101833A
Authority
BG
Bulgaria
Prior art keywords
proizvodno
guaninovo
valinatehydrochloride
valacycloride
itspreparation
Prior art date
Application number
BG101833A
Other languages
English (en)
Other versions
BG63393B1 (bg
Inventor
Barrry CARTER
Jane PARTIN
Peter VARLASHKIN
Richard WINNIKE
III William GRUBB
Gregory CONWAY
Philip Lake
David SKINNER
David WHATRUP
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG101833(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of BG101833A publication Critical patent/BG101833A/bg
Publication of BG63393B1 publication Critical patent/BG63393B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Изобретението се отнася до безводна кристална форма на [2- (2-амино-1,6-дихидро-6-оксо-пурин-9-ил) метокси]етил L-валинат хидрохлорид (известен като валацикловир хидрохлорид), съдържащ не повече от 3% тегл. хидратна вода, и до метод за получаването му.
BG101833A 1995-01-20 1997-08-14 Гуаниново производно BG63393B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (2)

Publication Number Publication Date
BG101833A true BG101833A (bg) 1998-04-30
BG63393B1 BG63393B1 (bg) 2001-12-29

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101833A BG63393B1 (bg) 1995-01-20 1997-08-14 Гуаниново производно

Country Status (40)

Country Link
US (1) US6107302A (bg)
EP (1) EP0804436B1 (bg)
JP (1) JP3176633B2 (bg)
KR (1) KR100376074B1 (bg)
CN (1) CN1049893C (bg)
AP (1) AP662A (bg)
AR (1) AR002270A1 (bg)
AT (1) ATE302777T1 (bg)
AU (1) AU702794B2 (bg)
BG (1) BG63393B1 (bg)
BR (1) BR9606768A (bg)
CA (1) CA2210799C (bg)
CY (1) CY2531B1 (bg)
CZ (1) CZ297065B6 (bg)
DE (1) DE69635106T2 (bg)
DK (1) DK0804436T3 (bg)
EA (1) EA000364B1 (bg)
EE (1) EE03528B1 (bg)
ES (1) ES2248806T3 (bg)
FI (1) FI973063A7 (bg)
GB (1) GB9501178D0 (bg)
GE (1) GEP20001940B (bg)
HR (1) HRP960024B1 (bg)
HU (1) HU222993B1 (bg)
IL (1) IL116831A (bg)
IN (1) IN182468B (bg)
IS (1) IS2268B (bg)
NO (1) NO315558B1 (bg)
NZ (1) NZ298851A (bg)
OA (1) OA10499A (bg)
PL (1) PL182175B1 (bg)
RO (1) RO118693B1 (bg)
RS (1) RS49518B (bg)
SI (1) SI0804436T1 (bg)
SK (1) SK285329B6 (bg)
TR (1) TR199700656T1 (bg)
UA (1) UA46001C2 (bg)
UY (1) UY25779A1 (bg)
WO (1) WO1996022291A1 (bg)
ZA (1) ZA96449B (bg)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
CA2243237C (en) * 1996-01-19 2008-09-02 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
CN1250449A (zh) * 1997-01-17 2000-04-12 味之素株式会社 新型z－伐昔洛韦结晶
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
PT1368349E (pt) * 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como medicamento
US6849736B2 (en) * 2001-09-07 2005-02-01 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1575953A1 (en) * 2002-12-09 2005-09-21 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
WO2005000850A2 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries, Ltd. Novel crystalline forms of valacyclovir hydrochloride
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1761535A1 (en) * 2004-06-30 2007-03-14 Teva Pharmaceutical Industries Ltd Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
US7846937B2 (en) * 2005-05-25 2010-12-07 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2735562C (en) * 2008-08-15 2017-10-17 Boehringer Ingelheim International Gmbh Dpp-4 inhibitors for wound healing
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CA2782179C (en) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
KR102018038B1 (ko) 2010-06-24 2019-09-05 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
PL3517539T3 (pl) 2011-07-15 2023-04-24 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
WO2013076688A1 (en) * 2011-11-25 2013-05-30 Piramal Enterprises Limited A process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
NZ747331A (en) 2016-06-10 2025-06-27 Boehringer Ingelheim Int Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ES2157259T3 (es) * 1993-06-10 2001-08-16 Rolabo Sl Procedimiento para preparar esteres de aminoacidos y analogos de nucleosidos.
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
CZ229497A3 (en) 1997-12-17
BR9606768A (pt) 1997-12-30
PL321326A1 (en) 1997-12-08
KR19980701525A (ko) 1998-05-15
RO118693B1 (ro) 2003-09-30
CZ297065B6 (cs) 2006-08-16
HRP960024A2 (en) 1997-10-31
RS49518B (sr) 2006-10-27
YU3396A (sh) 1998-12-23
AU702794B2 (en) 1999-03-04
SK96597A3 (en) 1998-02-04
SK285329B6 (sk) 2006-11-03
EP0804436B1 (en) 2005-08-24
AR002270A1 (es) 1998-03-11
AP9701058A0 (en) 1997-10-31
IL116831A (en) 1998-10-30
GEP20001940B (en) 2000-02-05
ZA96449B (en) 1996-08-07
CA2210799A1 (en) 1996-07-25
HRP960024B1 (en) 2005-08-31
FI973063A0 (fi) 1997-07-18
DK0804436T3 (da) 2005-12-27
EE03528B1 (et) 2001-10-15
JP3176633B2 (ja) 2001-06-18
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
NO315558B1 (no) 2003-09-22
EA199700124A1 (ru) 1997-12-30
CN1179159A (zh) 1998-04-15
ATE302777T1 (de) 2005-09-15
AU4453996A (en) 1996-08-07
NO973326L (no) 1997-09-16
CA2210799C (en) 2008-06-10
NO973326D0 (no) 1997-07-18
NZ298851A (en) 1999-01-28
IN182468B (bg) 1999-04-17
HUP9801836A2 (hu) 1999-05-28
UA46001C2 (uk) 2002-05-15
SI0804436T1 (sl) 2006-02-28
DE69635106D1 (de) 2005-09-29
IL116831A0 (en) 1996-05-14
AP662A (en) 1998-08-19
ES2248806T3 (es) 2006-03-16
FI973063L (fi) 1997-09-18
EA000364B1 (ru) 1999-06-24
WO1996022291A1 (en) 1996-07-25
FI973063A7 (fi) 1997-09-18
HUP9801836A3 (en) 1999-06-28
GB9501178D0 (en) 1995-03-08
UY25779A1 (es) 2000-08-21
JPH11503718A (ja) 1999-03-30
IS2268B (is) 2007-07-15
TR199700656T1 (xx) 1998-03-21
HU222993B1 (hu) 2004-01-28
EP0804436A1 (en) 1997-11-05
EE9700175A (et) 1998-02-16
DE69635106T2 (de) 2006-06-08
IS4527A (is) 1997-07-15
MX9705462A (es) 1997-10-31
CY2531B1 (en) 2006-04-12
OA10499A (en) 2002-04-10
US6107302A (en) 2000-08-22
PL182175B1 (pl) 2001-11-30
KR100376074B1 (ko) 2003-06-02

Similar Documents

Publication Publication Date Title
BG101833A (bg) Гуаниново производно
ES2145915T3 (es) Derivados estereoquimicos de la wortmannina.
DE69709938D1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
BG102474A (bg) (-)-цис-6(s)-фенил-5(r)-[4-(2-пиролидин-1-илетокси) фенил]-5,6,7,8-тетрахидронафтален-2-ол d-тартарат
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
PL319605A1 (en) Novel benzoxazoles
IL135590A (en) Process for the reduction of oxiranyl epothilones to olefinic epothilones
BG103485A (bg) Кетобензамиди като инхибитори на калпаина
MX9801190A (es) Inhibidores de prolil endopeptidasa.
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
FI20000553L (fi) Proteaasi-inhibiittoreina käyttökelpoisten 4-hydroksi-2-oksopyraanijohdannaisten valmistusmenetelmä
IL125002A0 (en) Novel substituted 4-(1H-benzimidazol-2-yl) [1,4] diazepanes useful for the treatment of allergic diseases
BG103649A (bg) Метод за получаване на епросартан
FI963054L (fi) Menetelmä HIV-proteaasi-inhibiittoreiden valmistamiseksi
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
BG103650A (bg) Метод за получаване на епросартан
FI973644L (fi) Uusi menetelmä 2,3-dihydrobentsofuranolijohdannaisten valmistamiseksi
MX9603348A (es) Derivados de disulfuro de amida indano-2-mercaptoacetilica novedosos utiles como inhibidores de encefalinasa.
EA200001153A1 (ru) Очистка карбоксальдегида
FI960332A7 (fi) Menetelmä substituoitujan 4,6-diamino-5-syanopyrinidiinien valmistamiseksi
FI972389A0 (fi) Uusi menetelmä ranitidiinin valmistamiseksi
BG103321A (bg) Метод за получаване на феноксифенилсулфонилни халогениди
YU71400A (sh) Poboljšani postupak za pripremanje farmaceutski dragocenih derivata norbenzomorfana
UA70975C2 (uk) Похідні 1,4-діарил-2-фтор-1-бутен-3-олу, спосіб їх одержання та способи одержання похідних 1,4-діарил-2-фтор-1,3-бутадієну і 1,4-діарил-2-фтор-2-бутену
ITTO920113A1 (it) Procedimento per la fabbricazione di cravatte.